Rare Insights

Exploring the ideas, innovations, and individuals shaping the future of rare disease.

EU JCA readiness: early signals for development teams

EU Joint Clinical Assessment (JCA) is still early in its implementation. Much of the formal framework is[…]

Why 2026 matters for EU Joint Clinical Assessment readiness

As we move into 2026, EU Joint Clinical Assessments (JCAs) are shifting from policy concept to operational[…]

We use cookies in order to give you the best possible experience on our website. By continuing to use this site, you agree to our use of cookies.
Accept